Coming Soon...
Late abstract submissions are now closed!
Take advantage of the opportunity to have your latest research in hepatitis and liver disease peer-reviewed, published and featured in the GHS 2023 Scientific Program.
The Global Hepatitis Summit Scientific Program reserves integrated parallel presentation slots within dedicated sessions that span across the three pillars: Clinical Science, Basic Science, and Public Health. This means you could present in the same sessions as your mentors, role models, colleagues, and peers!
Synonymous to the congress theme; the continuum of research from basic science to clinical science and public health applications; browse the abstract submission topics and submission guidelines to ensure a successful submission.
ENCORE ABSTRACTS CLOSED
Abstract submission guidelines
- Abstracts must be submitted electronically using the official online submission form
- Abstracts must identify the presenting author along with email address
- Please use standard abbreviations. Place special or unusual abbreviations in parenthesis after the full word when it appears for the first time
- Errors, misspellings, and incorrect abbreviations will not be corrected
- Abstracts will be presented in capital letter case
- An individual may submit more than one (1) abstract. One official online submission is required for each abstract
- Edits to submitted abstracts may be made up to the submission deadline. Instructions for making edits can be found on the submission site
Abstract types
During the online abstract submission, authors will be requested to select their preferred method of presentation: Oral/ Poster Presentation or Poster only Presentation.
Presentation method preferences will be considered during the review process.
Session themes (topics)
Themes (topics) for each of the sessions are listed below. Please submit your abstract within the Basic Science, Clinical or Public Health streams under one of the following subtopics:
- HCV/flavivirus virology
- HCV immunology
- HBV/HDV virology
- HBV/HDV treatment targets
- NASH targets for new therapies
- Hepatocellular carcinoma targets for new therapies
- HEV virology and persistence
- Liver inflammation and fibrogenesis
- Miscellaneous basic
- Artificial intelligence in liver disease management
- Difficult-to-treat HCV patients
- New strategies with approved HBV treatments
- New HBV drug clinical developments
- New HDV therapies
- Long-term outcomes of treated patients with viral hepatitis
- NAFLD/NASH therapeutic developments
- Impacts of COVID-19 on liver disease management
- Hepatocellular carcinoma new drug clinical trials
- Viral hepatitis and liver transplantation
- New biomarkers for liver diseases
- New developments in liver pathogen detection and discovery
- Miscellaneous clinical
- Epidemiology of HCV in resource-limited countries
- Global epidemiology of HBV/HDV infections
- Viral hepatitis elimination achievements and challenges
- Simplified approaches for screening and diagnosis of viral hepatitis
- Reaching vulnerable populations for viral hepatitis elimination
- Miscellaneous public health
The abstract review committee reserves the right to reassign submitted abstracts to a different session.
Abstract formatting guidelines
Please adhere to the following formatting guidelines when submitting your abstracts for GHS 2023. Abstracts that are not correctly formatted will not be reviewed.
- The abstract title should not exceed 300 characters
- The abstracts should not exceed 3,000 characters
- Each abstract is allowed to include a maximum of three (3) caption (figure or table) but this is not a requirement. Minimize the use of charts and graphics as this detail is not used to evaluate the merit of your abstract
- There is no restriction on your abstract structure, but we recommended the following:
- Title
- Background
- Purpose
- Method(s)
- Result(s)
- Conclusion(s)
Notification of acceptance
Presenting authors will be notified of their acceptance status on or before February 1, 2023. Presenting authors must inform any co-author(s) of acceptance. The organizing committee reserves the right to accept or decline any submissions and to select the presentation format (oral or poster).
Disclosure of conflicts of interest
The presenting authors of abstracts selected for oral presentation will be required to complete and submit a Disclosure of Conflicts of Interest form after they are invited to present. Disclosures are due on or before the RSVP deadline.
Disclaimer regarding the submission of abstracts
The Conference Organizers will not be held responsible for abstract submissions not received via the website or for submission errors caused by internet service outages, hardware or software delays, power outages or unforeseen events.
For more info regarding abstract submissions, please contact: ghsabstract@mci-agency.com
